Where is ProMab located?

ProMab is headquartered in Richmond, United States.

How many employees does ProMab have?

As of May 31, 2026, the latest employee count at ProMab is 22.

Is ProMab a funded company?

ProMab is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does ProMab rank among its competitors?

ProMab ranks 56th amongst 272 active competitors, of which 16 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Y-Biologics, which secured $25.2M in Aug, 2025.

Who are the top competitors of ProMab?

ProMab's top competitors include Sino Biological, GenScript and Y-Biologics. Among them, Y-Biologics secured the most recent funding round in August, 2025.

ProMab - 2026 Company Profile, Team & Competitors

ProMab is an unfunded company based in Richmond (United States), founded in 2001. It operates as a Custom antibody, CAR-T, and mRNA-LNP services and products provider. ProMab has not raised any funding yet. The company has 272 active competitors, including 16 funded and 39 that have exited. Its top competitors include companies like Sino Biological, GenScript and Y-Biologics.

Company Details

Custom antibody, CAR-T, and mRNA-LNP services and products provider. This is a biotechnology company specializing in developing and commercializing innovative solutions for the biomedical research community. They offer a wide range of products including antibodies, proteins, CAR-T/NK cells, and mRNA-Lipid Nanoparticles. Their services encompass CAR-T/NK development, mRNA-LNP gene delivery, custom antibody engineering and production, cell-based assays, and protein expression. They leverage expertise in bioinformatics, molecular biology, protein expression, and immunology to provide cutting-edge technologies. The company focuses on improving human health through immunotherapy, particularly CAR-T/NK cell technologies. They offer custom research services to advance the use of LNP-based delivery of mRNAs, including the development of vaccines, engineered immune cells, or antibody-encoding mRNA solutions. They also provide lentivirus production and licensing of CAR technology. The website includes login, account, cart, search, FAQ, protocols, technology, troubleshooting, news, publications, careers, contact us, promotions, codes & coupons, and sign-up for news & promotions.

Website: www.promab.com/
Social

Key Metrics

Founded Year

2001

Location

Richmond, United States

Stage

Unfunded

Ranked

56^th among 272 active competitors

Employee Count

22 as on May 31, 2026

Similar Companies

Sino Biological & 329 more

View ProMab's full profile

ProMab has not raised any funding rounds yet.

ProMab's employee count trend

ProMab has 22 employees as of May 26. Here is ProMab's employee count trend over the years:

Uncover ProMab's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ProMab include Sino Biological, GenScript and Y-Biologics. Here is the list of Top 10 competitors of ProMab, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sino Biological 2007, Beijing (China), Series A	Provider of reagents,and kits for clinical research	$29.4M	CTS Capital, Qiming Venture Partners & 1 others	64/100
2nd	GenScript 2002, Piscataway (United States), Public	Provider of reagents and instruments for life sciences research	$15M	Kleiner Perkins, Vermögensclub & 1 others	59/100
3rd	Y-Biologics 2007, Daejeon (South Korea), Public	Developer of antibodies for the treatment of multiple diseases	$42.1M	InterVest, IMM Investment & 14 others	56/100
4th	Shanghai OPM Biosciences 2013, Pudong (China), Series B	Antibody culture media and vaccine culture products developer	$14.4M	CPE, China Life Great Health Fund & 5 others	54/100
5th	Allele Biotech 1999, San Diego (United States), Series B	cGMP iPSCs and cell therapy CDMO accelerating regenerative medicine programs	$18M	NIH, HHS & 1 others	52/100
6th	Bio X Cell 1997, Lebanon (United States), Acquired	Provider of antibodies and antibody production services for in vivo use	-	-	50/100
7th	ITBMed 2016, Stockholm (Sweden), Series A	Developer of monoclonal antibodies to prevent transplant rejections	$87M	Yonjin Capital, 3E Bioventures Capital & 2 others	50/100
8th	Mabtech 1986, Nacka (Sweden), Acquired	Develops antibodies and ELISA kits	-	Merieux Equity Partners, IK Partners & 1 others	50/100
9th	Pixelgen Technolgies 2020, Stockholm (Sweden), Series A	Developer of ground-breaking technologies for biomedical research and diagnostics	$6M	Industrifonden, Navigare Ventures & 1 others	50/100
10th	Immuno-Biological Laboratories 1982, Fujioka (Japan), Public	Manufacture antibodies	-	Japan Asia Investment, Whiz Partners & 3 others	49/100
56th	ProMab 2001, Richmond (United States), Unfunded	Custom antibody, CAR-T, and mRNA-LNP services and products provider	-	-	30/100